Canada Pension Plan Investment Board Purchases 72,900 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Canada Pension Plan Investment Board raised its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 230.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 104,600 shares of the specialty pharmaceutical company’s stock after purchasing an additional 72,900 shares during the quarter. Canada Pension Plan Investment Board owned 0.17% of Jazz Pharmaceuticals worth $13,539,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. BlackRock Inc. lifted its holdings in Jazz Pharmaceuticals by 3.3% during the second quarter. BlackRock Inc. now owns 6,879,285 shares of the specialty pharmaceutical company’s stock valued at $852,825,000 after purchasing an additional 222,801 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Jazz Pharmaceuticals by 2.3% during the third quarter. Vanguard Group Inc. now owns 5,888,766 shares of the specialty pharmaceutical company’s stock valued at $784,914,000 after buying an additional 131,570 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Jazz Pharmaceuticals by 7.5% during the first quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company’s stock valued at $408,654,000 after buying an additional 184,124 shares during the last quarter. State Street Corp raised its position in shares of Jazz Pharmaceuticals by 1.8% during the second quarter. State Street Corp now owns 2,372,395 shares of the specialty pharmaceutical company’s stock valued at $294,106,000 after buying an additional 42,703 shares during the last quarter. Finally, LSV Asset Management raised its position in shares of Jazz Pharmaceuticals by 2.4% during the third quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company’s stock valued at $307,055,000 after buying an additional 55,630 shares during the last quarter. Hedge funds and other institutional investors own 88.15% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. UBS Group cut shares of Jazz Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $170.00 to $135.00 in a research report on Monday, November 27th. Robert W. Baird assumed coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $160.00 price target on the stock. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 30th. Truist Financial restated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, December 4th. Finally, Barclays reduced their price target on shares of Jazz Pharmaceuticals from $240.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, January 29th. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $195.90.

Get Our Latest Stock Analysis on Jazz Pharmaceuticals

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, Director Mark Douglas Smith sold 417 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $119.27, for a total transaction of $49,735.59. Following the completion of the sale, the director now directly owns 6,888 shares of the company’s stock, valued at $821,531.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Trading Up 0.6 %

JAZZ stock opened at $123.43 on Monday. The company has a quick ratio of 1.67, a current ratio of 2.06 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a twelve month low of $111.25 and a twelve month high of $152.90. The stock has a market capitalization of $7.77 billion, a price-to-earnings ratio of 140.26, a price-to-earnings-growth ratio of 0.94 and a beta of 0.62. The firm’s fifty day simple moving average is $122.07 and its two-hundred day simple moving average is $127.82.

Jazz Pharmaceuticals Company Profile

(Free Report)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.

Further Reading

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.